COEP - NASDAQ
Coeptis Therapeutics, Inc.
$16.40
+0.0000%Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
At a Glance
Live SnapshotCoeptis Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Coeptis Therapeutics, Inc. Cash Flow Statement
COEP • NASDAQ
| Coeptis Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2005 | Dec 2004 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-11.9M | -10.9M | -21.3M | -37.6M | -13.4M | -9.2M | -2.2K | -344.3K | 2.6M | |
1.2M | 1M | 1M | 1M | 447.4K | 323.4K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 5.3M | 0.0 | 0.0 | 0.0 | 0.0 | |
1.2M | 1.1M | 477.5K | 0.0 | 1.9M | 0.0 | 0.0 | 0.0 | 0.0 | |
2.3M | 2.2M | 10.8M | 33.2M | 4.3M | 3M | -88.3K | 0.0 | 0.0 | |
-1.5M | -125.3K | 1.7M | -550.3K | -3M | 2.7M | 450.0 | -72.7K | -1.1M | |
-8.6M | -6.6M | -7.2M | -3.9M | -4.5M | -3.1M | -90.1K | -417K | 1.6M | |
INVESTING ACTIVITIES | |||||||||
(0.0) | (0.0) | (0.0) | (0.0) | -1.8M | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -75.8M | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | -1.8M | -75.8M | (0.0) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||||||
13M | 100K | 5.3M | 3.3M | 9.9M | 1.1M | 0.0 | 0.0 | 0.0 | |
771.3K | 1.2M | -575K | -2.4M | -1.6M | 1.8M | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | -247.2K | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 500K | 200K | 4.6M | -50.9K | 0.0 | 90.6K | 570.2K | -1.6M | |
13.7M | 5.7M | 4.9M | 5.5M | 8.2M | 2.9M | 90.6K | 570.2K | -1.6M | |
CASH FLOW SUMMARY | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 75.8M | 0.0 | 0.0 | 0.0 | |
5.1M | -936.2K | -2.3M | 1.6M | 2M | -237.1K | 505.0 | 153.2K | 383.0 | |
532.9K | 1.5M | 3.8M | 2.2M | 203K | 440.1K | 0.0 | 383.0 | 0.0 | |
5.7M | 532.9K | 1.5M | 3.8M | 2.2M | 203K | 505.0 | 153.6K | 383.0 | |
-8.6M | -6.6M | -7.2M | -3.9M | -6.2M | -3.1M | -90.1K | -417K | 1.6M |
SEC Filings
COEP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 01, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 07, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 04, 2026 | January 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 12, 2026 | 2026 | |
S-4/A S-4/A (Amended) N/A | December 22, 2025 | December 22, 2025 |
Related Guides
Continue your COEP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.